Stories
Zydus and MSN Launch First Generic Adempas in US Markets
C
CNBC TV18•05-10-2026, 21:23
Zydus and MSN Launch First Generic Adempas in US Markets
- •Zydus Lifesciences and MSN Laboratories have launched the first generic version of Adempas (riociguat) in the United States.
- •The tablets are available in five strengths after receiving approval from the US Food and Drug Administration.
- •Riociguat is prescribed to treat adults with rare and potentially life-threatening conditions like pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension.
- •The launch provides a lower-cost alternative for patients who typically require lifelong treatment, breaking the previous monopoly of the branded product.
- •Bayer reported global sales of Adempas at around $850 million in 2025, highlighting the significant market opportunity for this rollout.
Key Questions Answered
Zydus Lifesciences and MSN Laboratories launched the first generic version of Adempas (riociguat) in the US market after receiving USFDA approval.
Riociguat is used to treat adults with pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH), two rare and potentially life-threatening conditions.
According to Bayer's 2025 annual report, global sales of Adempas reached around €745 million, or approximately $850 million, in 2025.
